208 related articles for article (PubMed ID: 26555472)
21. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T
J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058
[TBL] [Abstract][Full Text] [Related]
22. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
23. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
Rathouska J; Vecerova L; Strasky Z; Slanarova M; Brcakova E; Mullerova Z; Andrys C; Micuda S; Nachtigal P
Pharmacol Res; 2011 Jul; 64(1):53-9. PubMed ID: 21440631
[TBL] [Abstract][Full Text] [Related]
24. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
25. Activation of TGF-β receptors and Smad proteins by atorvastatin is related to reduced atherogenesis in ApoE/LDLR double knockout mice.
Vecerova L; Strasky Z; Rathouska J; Slanarova M; Brcakova E; Micuda S; Nachtigal P
J Atheroscler Thromb; 2012; 19(2):115-26. PubMed ID: 22104174
[TBL] [Abstract][Full Text] [Related]
26. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
[TBL] [Abstract][Full Text] [Related]
27. Artesunate attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through inhibition of pro-inflammatory cytokines and pro-inflammatory chemokines.
Jiang W; Cen Y; Song Y; Li P; Qin R; Liu C; Zhao Y; Zheng J; Zhou H
Phytomedicine; 2016 Oct; 23(11):1259-66. PubMed ID: 27316397
[TBL] [Abstract][Full Text] [Related]
28. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
[TBL] [Abstract][Full Text] [Related]
29. The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice.
Tian GP; Tang YY; He PP; Lv YC; Ouyang XP; Zhao GJ; Tang SL; Wu JF; Wang JL; Peng J; Zhang M; Li Y; Cayabyab FS; Zheng XL; Zhang DW; Yin WD; Tang CK
Biochem Biophys Res Commun; 2014 Jan; 443(2):428-34. PubMed ID: 24309104
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
[TBL] [Abstract][Full Text] [Related]
31. The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Mörk LM; Rehnmark S; Davoodpour P; Norata GD; Larsson L; Witt MR; Malm J; Parini P
PLoS One; 2013; 8(12):e78534. PubMed ID: 24324578
[TBL] [Abstract][Full Text] [Related]
32. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
[TBL] [Abstract][Full Text] [Related]
33. EphA2 knockdown attenuates atherosclerotic lesion development in ApoE(-/-) mice.
Jiang H; Li X; Zhang X; Liu Y; Huang S; Wang X
Cardiovasc Pathol; 2014; 23(3):169-74. PubMed ID: 24561077
[TBL] [Abstract][Full Text] [Related]
34. Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing B1a lymphocytes.
Hosseini H; Li Y; Kanellakis P; Tay C; Cao A; Tipping P; Bobik A; Toh BH; Kyaw T
Cardiovasc Res; 2015 Jun; 106(3):443-52. PubMed ID: 25681396
[TBL] [Abstract][Full Text] [Related]
35. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
36. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
[TBL] [Abstract][Full Text] [Related]
37. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens.
Malina DM; Fonseca FA; Barbosa SA; Kasmas SH; Machado VA; França CN; Borges NC; Moreno RA; Izar MC
J Clin Lipidol; 2015; 9(4):542-52. PubMed ID: 26228672
[TBL] [Abstract][Full Text] [Related]
38. Murine Norovirus Infection Variably Alters Atherosclerosis in Mice Lacking Apolipoprotein E.
Hsu CC; Paik J; Brabb TL; O'Brien KD; Kim J; Sullivan BG; Hudkins KL; Seamons A; Finley JC; Meeker SM; Maggio-Price L
Comp Med; 2015 Oct; 65(5):369-81. PubMed ID: 26473341
[TBL] [Abstract][Full Text] [Related]
39. Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin.
Ekstrand M; Gustafsson Trajkovska M; Perman-Sundelin J; Fogelstrand P; Adiels M; Johansson M; Mattsson-Hultén L; Borén J; Levin M
PLoS One; 2015; 10(6):e0130898. PubMed ID: 26098110
[TBL] [Abstract][Full Text] [Related]
40. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
